Department of Oncology and Hematology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518033, China.
College of Medicine, Yangzhou University, Yangzhou 225001, China.
J Tradit Chin Med. 2023 Jun;43(3):568-573. doi: 10.19852/j.cnki.jtcm.20230227.001.
To investigate the benefits of Traditional Chinese Medicine (TCM) therapy for improving the survival of patients with stage I gastric cancer (GC) and high-risk factors in a real-world setting.
The clinical data of patients who were diagnosed with stage I GC from March 1, 2012 to October 31, 2020 were collected. Prognostic analysis was performed to explore the high-risk factors that affected the survival of the patients. A Cox multivariate regression model was used to compare the hazard ratios for the mortality risk of patients, especially those with high-risk factors. Kaplan-Meier survival curve and log-rank test were utilized to assess the survival time.
Prognostic analysis demonstrated that female sex, tumor invasion into blood vessels, and Ib stage were independent risk factors. The 1-, 3-, and 5-year survival rates of the TCM group those of the non-TCM group were 100.0% 91.0%, 97.6% 64.5%, and 81.4% 55.5%, respectively. A significant difference in median overall survival (mOS) was found between the two groups (χ = 7.670, = 0.006). Subgroup analysis showed that the mOS of female patients and stage Ib patients in the TCM group were longer than those in the non-TCM group ( ≤ 0.001 and 0.001, respectively).
TCM treatment can improve the survival of patients with stage I GC and high-risk factors.
在真实世界环境中，探究中医治疗对提高 I 期胃癌（GC）患者及高危因素患者生存率的获益。
收集 2012 年 3 月 1 日至 2020 年 10 月 31 日期间诊断为 I 期 GC 的患者的临床资料，对影响患者生存的高危因素进行预后分析，采用 Cox 多因素回归模型比较患者的死亡风险的危险比，尤其是高危因素患者。采用 Kaplan-Meier 生存曲线和对数秩检验评估生存时间。
预后分析显示，女性、肿瘤侵犯血管和 Ib 期是独立的危险因素。TCM 组与非 TCM 组患者的 1、3、5 年生存率分别为 100.0%、91.0%、97.6%和 64.5%、55.5%、55.5%。两组患者中位总生存期（mOS）存在显著差异（χ = 7.670，= 0.006）。亚组分析显示，TCM 组女性和 Ib 期患者的 mOS 均长于非 TCM 组（≤0.001 和 0.001）。
中医治疗可以提高 I 期 GC 及高危因素患者的生存率。
